| Community-Acquired Pneumonia

Nuzyra vs Teflaro

Side-by-side clinical, coverage, and cost comparison for community-acquired pneumonia.

Deep comparison between: Nuzyra vs Teflaro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTeflaro has a higher rate of injection site reactions vs Nuzyra based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Teflaro but not Nuzyra, including UnitedHealthcare

Category

Nuzyra

Teflaro

At A Glance

RouteIV infusion or Oral

FrequencyOnce daily

ClassAminomethylcycline (tetracycline class)

RouteIV infusion

FrequencyEvery 12 hours

ClassCephalosporin antibacterial

Indications

Community-Acquired Pneumonia
Skin Diseases, Bacterial

Acute bacterial skin and skin structure infection
Community-Acquired Pneumonia

Dosing

Community-Acquired Pneumonia Loading: IV 200 mg over 60 min or IV 100 mg over 30 min twice or Oral 300 mg twice on Day 1; Maintenance: IV 100 mg over 30 min once daily or Oral 300 mg once daily; duration 7 to 14 days.

Skin Diseases, Bacterial Loading: IV 200 mg over 60 min or IV 100 mg over 30 min twice on Day 1 or Oral 450 mg once daily on Days 1 and 2; Maintenance: IV 100 mg over 30 min once daily or Oral 300 mg once daily; duration 7 to 14 days.

Acute bacterial skin and skin structure infection Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-14 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours; neonates (gestational age >=34 weeks, postnatal age >=12 days) to <2 months: 6 mg/kg every 8 hours over 30 to 60 minutes.

Community-Acquired Pneumonia Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-7 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours over 5 to 60 minutes for 5-14 days.

Contraindications

Known hypersensitivity to omadacycline, tetracycline class antibacterial drugs, or any excipient

Known serious hypersensitivity to ceftaroline or other members of the cephalosporin class

Drug Interactions

1026View drug interactions

1068View drug interactions

Adverse Reactions

Most common (>=2%) In CABP: ALT increased, hypertension, GGT increased, insomnia, vomiting, constipation, nausea, AST increased, headache. In ABSSSI: nausea, vomiting, infusion site reactions, ALT increased, AST increased, headache, diarrhea.

Serious Mortality imbalance in CABP patients (2% vs 1% comparator); tooth development effects and enamel hypoplasia; inhibition of bone growth; hypersensitivity reactions.

Most common (>=2%) Diarrhea, nausea, rash, constipation, vomiting, increased transaminases, hypokalemia, phlebitis

Serious Hypersensitivity reactions, anaphylaxis, Clostridioides difficile-associated diarrhea, neurological adverse reactions (dizziness, convulsion), direct Coombs' test seroconversion

Postmarketing Agranulocytosis, leukopenia, eosinophilic pneumonia, encephalopathy, seizures

Pharmacology

Omadacycline is an aminomethylcycline antibacterial within the tetracycline class that binds to the 30S ribosomal subunit and blocks protein synthesis; it is generally bacteriostatic but may demonstrate bactericidal activity against some isolates of S. pneumoniae and H. influenzae.

Ceftaroline is a cephalosporin antibacterial that exerts bactericidal activity by binding to essential penicillin-binding proteins (PBPs), including PBP2a in S. aureus and PBP2x in S. pneumoniae, and has in vitro activity against both Gram-positive and Gram-negative bacteria.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Nuzyra